Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383046 | 1.00 | L3MBTL1 (0.39) | L3MBTL1HTTCHRM1ALDH1A1RAB9A | |
| SCHEMBL385711 | 0.98 | L3MBTL1 (0.36) | L3MBTL1HTTCHRM1ALDH1A1RAB9A | |
| SCHEMBL385712 | 0.98 | L3MBTL1 (0.36) | L3MBTL1HTTCHRM1ALDH1A1RAB9A | |
| Alanine SCHEMBL4954723 | 0.90 | LTA4H (0.35) | L3MBTL1HTTCHRM1RAB9ADPP7 | |
| Glycine SCHEMBL4955873 | 0.87 | GLRA1 (0.36) | L3MBTL1CHRM1DPP7MMELTA4H | |
| Pyrrole SCHEMBL28327955 | 0.86 | L3MBTL1 (0.38) | L3MBTL1HTTALDH1A1GAAMEN1 | |
| Threonine SCHEMBL4955781 | 0.84 | SLC7A5 (0.36) | DPP7LTA4H | |
| Serine SCHEMBL4956028 | 0.82 | DPP7 (0.40) | L3MBTL1CHRM1DPP7MMELTA4H | |
| SCHEMBL15794935 | 0.79 | CHRM5 (0.41) | RAB9A | |
| SCHEMBL15794748 | 0.79 | CHRM5 (0.41) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761554-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | Biosource Pharm, Inc. (US) | 2007-03-14 | — | — | EP | claimed |
| US-20060281687-A1 | Cyclin groove inhibitors | CYCLACEL LIMITED (GB) | 2006-12-14 | — | — | US | claimed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| EP-1675868-A2 | CYCLIN GROOVE INHIBITORS | Cyclacel Limited (GB) | 2006-07-05 | — | — | EP | claimed |
| WO-2005042565-A2 | CYCLIN GROOVE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | claimed |
| EP-1512692-A2 | Novel inhibitors of prenylated pyrophosphate consuming enzymes | Universiteit Leiden (NL) | 2005-03-09 | — | — | EP | claimed |
| US-20040121941-A1 | Novel inhibitors of prenylated pyrophosphate consuming enzymes | RIJKSUNIVERSITEIT LEIDEN (NL) | 2004-06-24 | — | — | US | claimed |
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | UNIV MICHIGAN (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4680108-A1 | PEPTIDE MULTIMER PRODUCTS AND METHODS | The Regents of The University of Michigan (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-08-21 | — | — | US | disclosed |
| US-20250263685-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION | 2025-08-21 | — | — | US | disclosed |
| EP-3660040-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4565333-A2 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | Regents of the University of Michigan (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-1270585-B1 | PEPTIDE DERIVATIVE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-05-17 | — | — | EP | disclosed |
| US-7015306-B2 | Labeled neurotensin derivatives | BIOSYNTHEMA, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| WO-2005042565-A3 | CYCLIN GROOVE INHIBITORS | CYCLACEL LTD (GB) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005042565-A2 | CYCLIN GROOVE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005042565-A2 | CYCLIN GROOVE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
| US-20040116336-A1 | Peptide derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1270585-A1 | PEPTIDE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | TP53, TP53BP1, DDIT3 | L3MBTL1 355/4885HTT 4183/4885CHRM1 3749/4885 |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | ERBB2, EGFR, ERBB3 | L3MBTL1 3066/4885HTT 2632/4885CHRM1 4702/4885 |
| US-20060281687-A1 | Cyclin groove inhibitors | CCNC, CCNH, CCNI | L3MBTL1 620/4885HTT 3938/4885CHRM1 1576/4885 |
| US-20250263685-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | L3MBTL1 1472/4885HTT 901/4885CHRM1 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.